 "Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad")
The US Food and Drug Administration (USFDA) has issued Form 483 with five observations to an active pharmaceutical ingredients (API) plant of Dr Reddy's Laboratories Limited.
In a Bombay Stock Exchange (BSE) filing on Friday, the company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection.
"These observations are related to procedures and facility maintenance. We will address them comprehensively within the stipulated time," Dr Reddy's said in its BSE filing.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%